How Blockchain Can Improve the Pharma Manufacturing Supply Chain

| April 6, 2018

article image
The entire pharmaceutical industry has been booming, from the manufacturing of clinical trial materials to support research studies to the regulated medicines on the pharmacy shelves. It has been one of the top industry performers of the past three decades. By maintaining the highest safety and quality standards, many pharma business units along the supply chain, such as research and development materials, manufacturing, sales and marketing, have enjoyed rising profits. However, in recent years the industry has been showing a gradual decline in performance, due to the many challenges and “growing pains” facing the industry. Lost ingredients in the supply chain, inactive chemicals due to inefficient cold-chain monitoring, wrongly prescribed medicines from faulty computer systems, counterfeit medicines because of gaps in security — all of these significant challenges have created demand for utilization of the latest technology to maintain visibility across the supply chain. It has come to the attention in many pharmaceutical communities that Blockchain technology can effectively repair all of these problems.

Spotlight

Genetics & Health

We are a company dedicated to providing services of genetic studies for rare diseases, seeking to encourage among specialists the use of genetics as part of their clinical practice in order to help them make better diagnoses and prescribe more effective treatments for the benefit of patients.

OTHER ARTICLES

What to Watch in 2020: Non-Specialty Drugs

Article | March 1, 2020

Pharmaceutical manufacturers are constantly working to develop new and improved medications. Join us as we explore the non-specialty drugs you should be watching in 2020. If you missed last week’s article about the most important upcoming specialty drugs, be sure to check it out here. Approximately 40 new medications are approved by the Food and Drug Administration (FDA) every year.1 (Please note: If you’re curious about what it takes to develop a drug and bring it to market, check out our previous article). Why should you care about these new medications? Because they can affect both your organization’s pharmacy spend and your members’ cost share. For non-specialty drugs, we will focus on medications that may come to market this year, including ones that are currently being reviewed by the FDA, or that are in the last clinical trial (Phase III) stage.

Read More

Clinical Supply Availability & Speed to Study Start-Up

Article | March 26, 2020

If you’re part of a clinical study team racing a new product to commercialization, you likely live by these two simple rules: time is money, and the first one to market wins. But just because it’s simple doesn’t mean it’s easy. That ticking clock is background noise to the responsibilities of regulations, study protocols, supply chains, and patient recruitment — all the details that must be worked out before a study can even begin. The pressure is always there. The longer it takes for a study to start, the longer it takes to complete.

Read More

Advance Your Pharma Supply Chain Planning during a Pandemic

Article | March 20, 2020

One predominant and common element within our pharmaceutical industry, is our devotions to patients. Within supply chain there is always a focus on ensuring the right product is delivered to the right place at the right time in order to ensure patient safety and the continuity of medicinal supplies. With the spread of COVID-19 across 117 countries and counting, every supply chain needs to evaluate their global footprint and develop contingency plans within their end to end operations.

Read More

Enabling Active Pharma Ingredients for Batch Balancing and Integration to SAP EWM

Article | April 6, 2020

Batch and its Classification system are two most potent weapons used in Chemical, Pharma or Medical life science industry to record the potency of a batch or technically called as Active Pharma Ingredients(API). These material consist of one or more active ingredients, concentrates, carrier materials, or impurities, and so on. The potency of the active ingredients varies from batch to batch. The active ingredient is the substance of greatest interest in the bill of materials, the proportion of which may vary from batch to batch. Therefore, during creation of a process order, the system must be able to select and adjust the batches needed to obtain the required amount of active ingredient. Take an example of a drug hydroxychloroquine which is used as potent weapon to fight COVID-19. This drug is manufactured by using API, however, the Potency of this API material vary from batch to batch. To map this kind of requirement in SAP ERP, SAP calls it as Material Quantity Calculation.

Read More

Spotlight

Genetics & Health

We are a company dedicated to providing services of genetic studies for rare diseases, seeking to encourage among specialists the use of genetics as part of their clinical practice in order to help them make better diagnoses and prescribe more effective treatments for the benefit of patients.

Events